Roquefort Therapeutics plc (LON:ROQ)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.975
-0.075 (-7.14%)
Mar 6, 2026, 4:35 PM GMT
-37.10%
Market Cap 1.60M
Revenue (ttm) n/a
Net Income (ttm) -882.45K
Shares Out 163.73M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,318,638
Average Volume 1,217,774
Open 1.080
Previous Close 1.050
Day's Range 0.975 - 1.080
52-Week Range 0.900 - 3.000
Beta -0.56
RSI 42.17
Earnings Date Apr 27, 2026

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in v... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 7
Stock Exchange London Stock Exchange
Ticker Symbol ROQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.